CompletedNot Applicable

Additive Role of ADC Value to ORADS in Adnexal Lesions

Egypt66 participantsStarted 2023-03-01

Plain-language summary

Evaluation of the impact of adding mean apparent diffusion coefficient (ADC mean) measurements to the Ovarian-Adnexal Imaging Reporting and Data System MRI (O-RADS MRI) scoring for adnexal lesion characterization using a combined O-RADS MRI/ADC mean reading approach.

Who can participate

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Female patient any age with adnexal lesions detected by U/S reported as O-RADS1and2.
✕. Cysts that were deemed to be clearly physiological and less than 3 cm in maximum diameter.
✕. No histopathological findings or follow-up \< one year .
✕. Previous bilateral adnexectomy.
✕. Contraindications to MRI examination including

What they're measuring

Mean ADC value of adnexal lesions

Timeframe: March 2023 to june 2024

Diagnostic performance of O-RADS MRI + ADC system

Timeframe: March 2023 to june 2024

Trial details

NCT IDNCT07202429

SponsorCairo University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-06-01

View on ClinicalTrials.gov More Ovarian Neoplasms trials